Shenzhen OK Biotech Technology Co., Ltd. (SZOB)
Product Categories

     Shenzhen OK Biotech Technology Co., Ltd.(SZOB)

     HK Add: 6/F, Fo Tan Industrial Centre, 26-28 Au Pui Wan St ,Fo Tan, Shatin, Hongkong

     China mainland Add: 8F, Fuxuan Building, No. 46, East Heping Rd, Longhua New  District,  Shenzhen, PRC China

     Email: nicole@ok-biotech.com

        smile@ok-biotech.com

     Web: www.ok-biotech.com

     Tel: +852 6679 4580

Ropivacaine HCL (132112-35-7)

Ropivacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to your brain.Ropivacaine is used as a local (in only one area) anesthesia for a spinal block, also called an epidural. The medication is used to provide anesthesia during a surgery or C-section, or to ease labor pains.Ropivacaine may also be used for purposes not listed in this medication guide.


What is Ropivacaine HCl anesthetic raw powder

Naropin Injection contains ropivacaine HCl, which is a member of the amino amide class of local anesthetics. Naropin (ropivacaine hcl) Injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and Water for Injection. Sodium hydroxide and/or hydrochloric acid may be used for pH adjustment. It is administered parenterally.、




How does Ropivacaine HCL anesthetic raw powder works?

Ropivacaine causes reversible inhibition of sodium ion influx, and thereby blocks impulse conduction in nerve fibres.This action is potentiated by dose-dependent inhibition of potassium channels.Ropivacaine is less lipophilic than bupivacaine and is less likely to penetrate large myelinated motor fibres; therefore, it has selective action on the pain-transmitting A and C nerves rather than A fibres, which are involved in motor function.




How is Ropivacaine HCL anesthetic raw powder given (Naropin, Naropin Polyamp, Naropin SDV)?

Ropivacaine is given as an injection through a needle placed into an area of your middle or lower back near your spine. You will receive this injection in a hospital or surgical setting.

Your breathing, blood pressure, oxygen levels, and other vital signs will be watched closely while you are receiving ropivacaine.

Some numbing medications can have long-lasting or delayed effects. Talk to your doctor if you have concerns about this risk. Call your doctor if you have joint pain or stiffness, or weakness in any part of your body that occurs after your surgery, even months later.




Dosage of Ropivacaine HCl anesthetic raw powder and administration

The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should always be used. The smallest dose and concentration required to produce the desired result should be administered.


There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Naropin is not approved for this use.


The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. Patients in poor general condition due to aging or other compromising factors such as partial or complete heart conduction block, advanced liver disease or severe renal dysfunction require special attention although regional anesthesia is frequently indicated in these patients. To reduce the risk of potentially serious adverse reactions, attempts should be made to optimize the patient's condition before major blocks are performed, and the dosage should be adjusted accordingly.


Use an adequate test dose (3 to 5 mL of a short acting local anesthetic solution containing epinephrine) prior to induction of complete block. This test dose should be repeated if the patient is moved in such a fashion as to have displaced the epidural catheter. Allow adequate time for onset of anesthesia following administration of each test dose.


Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Solutions that are discolored or that contain particulate matter should not be administered.




Warning of Ropivacaine HCl anesthetic raw powder

In performing Naropin (ropivacaine hcl) blocks, unintended intravenous injection is possible and may result in cardiac arrhythmia or cardiac arrest. The potential for successful resuscitation has not been studied in humans. There have been rare reports of cardiac arrest during the use of Naropin (ropivacaine hcl) for epidural anesthesia or peripheral nerve blockade, the majority of which occurred after unintentional accidental intravascular administration in elderly patients and in patients with concomitant heart disease. In some instances, resuscitation has been difficult. Should cardiac arrest occur, prolonged resuscitative efforts may be required to improve the probability of a successful outcome.


Naropin (ropivacaine hcl) should be administered in incremental doses. It is not recommended for emergency situations, where a fast onset of surgical anesthesia is necessary. Historically, pregnant patients were reported to have a high risk for cardiac arrhythmias, cardiac/circulatory arrest and death when 0.75% bupivacaine (another member of the amino amide class of local anesthetics) was inadvertently rapidly injected intravenously.


Prior to receiving major blocks the general condition of the patient should be optimized and the patient should have an i.v. line inserted. All necessary precautions should be taken to avoid intravascular injection. Local anesthetics should only be administered by clinicians who are well versed in the diagnosis and management of dose-related toxicity and other acute emergencies that may arise from the block to be employed, and then only after insuring the immediate (without delay) availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies (see also ADVERSE REACTIONS, 


PRECAUTIONS, and Managment of Local Anesthetic Emergencies). Delay in proper management of dose-related toxicity, underventilation from any cause, and/or altered sensitivity may lead to the development of acidosis, cardiac arrest and, possibly, death. Solutions of Naropin (ropivacaine hcl) should not be used for the production of obstetrical paracervical block anesthesia, retrobulbar block, or spinal anesthesia (subarachnoid block) due to insufficient data to support such use. Intravenous regional anesthesia (bier block) should not be performed due to a lack of clinical experience and the risk of attaining toxic blood levels of ropivacaine.


Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings. The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2nd month after surgery. Currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.


It is essential that aspiration for blood, or cerebrospinal fluid (where applicable), be done prior to injecting any local anesthetic, both the original dose and all subsequent doses, to avoid intravascular or subarachnoid injection. However, a negative aspiration does not ensure against an intravascular or subarachnoid injection.


A well-known risk of epidural anesthesia may be an unintentional subarachnoid injection of local anesthetic. Two clinical studies have been performed to verify the safety of Naropin (ropivacaine hcl) at a volume of 3 mL injected into the subarachnoid space since this dose represents an incremental epidural volume that could be unintentionally injected. The 15 and 22.5 mg doses injected resulted in sensory levels as high as T5 and T4, respectively. Anesthesia to pinprick started in the sacral dermatomes in 2 to 3 minutes, extended to the T10 level in 10 to 13 minutes and lasted for approximately 2 hours. The results of these two clinical studies showed that a 3 mL dose did not produce any serious adverse events when spinal anesthesia blockade was achieved.


Naropin (ropivacaine hcl) should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.


Patients treated with class III antiarrhythmic drugs (eg, amiodarone) should be under close surveillance and ECG monitoring considered, since cardiac effects may be additive.



What are the possible side effects of Ropivacaine (Naropin, Naropin Polyamp, Naropin SDV)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives or red skin rash; dizziness; sneezing; difficulty breathing; nausea or vomiting; sweating; swelling of your face, lips, tongue, or throat.


Tell your caregivers at once if you have any of these serious side effects:

  1. feeling anxious, restless, confused, or like you might pass out;

  2. problems with speech or vision;

  3. ringing in the ears, metallic taste, numbness or tingling around your mouth, or tremors;

  4. seizure (convulsions);

  5. weak or shallow breathing;

  6. slow heart rate, weak pulse; or

  7. fast heart rate, gasping, feeling unusually hot.


Less serious side effects include:

  1. nausea, vomiting;

  2. headache, back pain;

  3. fever;

  4. itching;

  5. numbness or tingly feeling; or

  6. problems with urination or sexual function.


This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Buy Ropivacaine HCl anesthetic raw powder from SZOB

Visit our online pharmacy and fill in an order of Ropivacaine HCl raw materials. Define place of delivery, quantity of the product and the way of payment. In the period of 30 minutes, you will receive a confirmation of your order. It will be delivered within 2 business days.





Hot Tags: Ropivacaine HCL raw,buy Ropivacaine HCL raw,Ropivacaine HCL,manufacturer,supplier,factory, buyRopivacaine HCL,Ropivacaine HCL works,dosage of Ropivacaine HCL,Warning of,Ropivacaine HCL,side effects of Ropivacaine HCL,buy Ropivacaine HCL,anesthetic raw powder,anesthetic raw,buy anesthetic raw powder,buy anesthetic raw,Ropivacaine HCL anesthetic raw powder,Ropivacaine HCL anesthetic raw,buy Ropivacaine HCL anesthetic raw,Ropivacaine HCL anesthetic raw powder,
I want to leave a message
Contact Us
Address: HK: 6/F,Fo Tan Industrial Centre,26-28 Au Pui Wan St,Fo Tan,Shatin,Hongkong Shenzhen: 8F, Fuxuan Building, No. 46, East Heping Rd, Longhua New District, Shenzhen, PRC China
Tel: +852 6679 4580
 Fax:+852 6679 4580
 E-mail:smile@ok-biotech.com
Shenzhen OK Biotech Technology Co., Ltd.(SZOB)
Share:
Verification: c5916f6aec73893e